Masaoki Ito1, Carles Codony-Servat1, Niki Karachaliou2, Rafael Rosell3. 1. Coyote Research Group, Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus, University Institute, Barcelona, Spain. 2. Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, QuironSalud Group, Barcelona, Spain. 3. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). However, universal progression is observed. METHODS: The effect of the anti-rheumatoid agent, auranofin, a selective inhibitor of oncogenic protein kinase C iota (PKCι) signaling and IPA-3, a non-ATP competitive p21-activated kinase 1 (PAK1) inhibitor in treatment-naïve and EGFR TKI-resistant EGFR-mutation positive NSCLC cell lines was investigated. PC9 and HCC827 cells were used. The four EGFR-TKI resistant cell lines were established from PC9. Cell viability assays, drug combination studies, and western blotting were performed. The combination index, and RTK or non-RTK expression were performed. RESULTS: The combination of IPA-3 and auranofin was highly synergistic in all 6 cell lines (combination indexes ranged from 0.37-0.62). The activities on EGFR, CDCP1, AXL, MET, and downstream effector pathways, including PAK1, PKCι, ERK, AKT, STAT3, Src, and YAP1 were abrogated. CONCLUSIONS: The combination of auranofin with IPA-3 could be a potential therapy for EGFR-mutation positive NSCLC resistant to EGFR TKIs. Auranofin with IPA-3 could become a therapeutic solution for EGFR-mutation positive NSCLC patients resistant to EGFR TKIs. 2019 Translational Lung Cancer Research. All rights reserved.
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). However, universal progression is observed. METHODS: The effect of the anti-rheumatoid agent, auranofin, a selective inhibitor of oncogenic protein kinase C iota (PKCι) signaling and IPA-3, a non-ATP competitive p21-activated kinase 1 (PAK1) inhibitor in treatment-naïve and EGFR TKI-resistant EGFR-mutation positive NSCLC cell lines was investigated. PC9 and HCC827 cells were used. The four EGFR-TKI resistant cell lines were established from PC9. Cell viability assays, drug combination studies, and western blotting were performed. The combination index, and RTK or non-RTK expression were performed. RESULTS: The combination of IPA-3 and auranofin was highly synergistic in all 6 cell lines (combination indexes ranged from 0.37-0.62). The activities on EGFR, CDCP1, AXL, MET, and downstream effector pathways, including PAK1, PKCι, ERK, AKT, STAT3, Src, and YAP1 were abrogated. CONCLUSIONS: The combination of auranofin with IPA-3 could be a potential therapy for EGFR-mutation positive NSCLC resistant to EGFR TKIs. Auranofin with IPA-3 could become a therapeutic solution for EGFR-mutation positive NSCLC patients resistant to EGFR TKIs. 2019 Translational Lung Cancer Research. All rights reserved.
Authors: Roderick P Regala; Capella Weems; Lee Jamieson; John A Copland; E Aubrey Thompson; Alan P Fields Journal: J Biol Chem Date: 2005-07-01 Impact factor: 5.157
Authors: Sean W Deacon; Alexander Beeser; Jami A Fukui; Ulrike E E Rennefahrt; Cynthia Myers; Jonathan Chernoff; Jeffrey R Peterson Journal: Chem Biol Date: 2008-04
Authors: Roderick P Regala; Capella Weems; Lee Jamieson; Andras Khoor; Eric S Edell; Christine M Lohse; Alan P Fields Journal: Cancer Res Date: 2005-10-01 Impact factor: 12.701
Authors: Verline Justilien; Michael P Walsh; Syed A Ali; E Aubrey Thompson; Nicole R Murray; Alan P Fields Journal: Cancer Cell Date: 2014-02-10 Impact factor: 31.743
Authors: Kirstine Jacobsen; Jordi Bertran-Alamillo; Miguel Angel Molina; Cristina Teixidó; Niki Karachaliou; Martin Haar Pedersen; Josep Castellví; Mónica Garzón; Carles Codony-Servat; Jordi Codony-Servat; Ana Giménez-Capitán; Ana Drozdowskyj; Santiago Viteri; Martin R Larsen; Ulrik Lassen; Enriqueta Felip; Trever G Bivona; Henrik J Ditzel; Rafael Rosell Journal: Nat Commun Date: 2017-09-04 Impact factor: 14.919
Authors: Ravi S Narayan; Carlos A Fedrigo; Eelke Brands; Rogier Dik; Lukas J A Stalpers; Brigitta G Baumert; Ben J Slotman; Bart A Westerman; Godefridus J Peters; Peter Sminia Journal: BMC Cancer Date: 2017-03-21 Impact factor: 4.430
Authors: Niki Karachaliou; Imane Chaib; Andres Felipe Cardona; Jordi Berenguer; Jillian Wilhelmina Paulina Bracht; Jie Yang; Xueting Cai; Zhigang Wang; Chunping Hu; Ana Drozdowskyj; Carles Codony Servat; Jordi Codony Servat; Masaoki Ito; Ilaria Attili; Erika Aldeguer; Ana Gimenez Capitan; July Rodriguez; Leonardo Rojas; Santiago Viteri; Miguel Angel Molina-Vila; Sai-Hong Ignatius Ou; Morihito Okada; Tony S Mok; Trever G Bivona; Mayumi Ono; Jean Cui; Santiago Ramón Y Cajal; Alex Frias; Peng Cao; Rafael Rosell Journal: EBioMedicine Date: 2018-02-05 Impact factor: 8.143